Running Seahorse Assays on T Cells
The three problems
| Problem | Consequence | Workaround |
|---|---|---|
| Non-adherent cells | Cells settle and are disturbed by injection | Cell-Tak, Matrigel, or a confluent feeder layer |
| Low cell number per well | Signal near noise; high variance | Pool wells; use the smallest plate format available |
| Assay buffer differs from culture medium | The cell is measured after a medium switch | Pre-equilibrate ≥ 1 h; report the buffer composition |
The third problem is the one that most changes interpretation. The assay buffer is bicarbonate-free so that pH can be measured, contains no serum, and is often glucose-limited. A cell measured 60 minutes after transfer to that buffer is a cell responding to transfer.
Cell number
| Plate format | Cells per well | Notes |
|---|---|---|
| 96-well | 2–5 × 10⁵ | Typical for activated T cells |
| 24-well | 5 × 10⁵ – 1 × 10⁶ | Lower variance; more material |
| 384-well | 5 × 10⁴ – 1 × 10⁵ | Only for high-flux populations |
Signal scales roughly with cell number, but not linearly at high density because of local nutrient depletion in a non-perfused well. Two densities should be run when a condition is new, and the linear range documented.
Readout note. Report OCR and ECAR per cell, using a terminal count of the same well (CyQUANT, or nuclei counting). Protein normalisation is unreliable for T cells: activation changes protein content per cell by several fold, so a per-microgram value can move in the opposite direction to a per-cell value.
Immobilisation
| Method | Mechanism | Effect on the measurement |
|---|---|---|
| Cell-Tak | Adhesive protein coating | Minimal metabolic effect; requires careful coating consistency |
| Matrigel or poly-D-lysine | Matrix coating | Integrin signalling can alter activation state |
| Feeder monolayer | Adherence by proxy | Feeder cells contribute to the signal |
| None (settling) | Gravity | Injection disturbs the cells; high variance |
Caveat on coatings. Integrin engagement is not metabolically inert. A T cell adhering to a matrix is receiving a costimulatory-like signal, and the measured flux includes that. Where the comparison is between activation states, a constant coating is a controlled variable; where the comparison is with a suspension measurement, it is not.
Assay medium
| Component | Standard choice | Why |
|---|---|---|
| Base | Seahorse XF base medium, or DMEM without bicarbonate | pH measurement requires low buffering |
| Glucose | Match the culture concentration, then test a lower one | 11 mM versus 5 mM changes the baseline |
| Glutamine | 1–2 mM | Substrate for the alternative route |
| Pyruvate | Optional; state whether present | Feeds the alternative route |
| Serum | Absent | Required for pH stability, but changes lipid availability |
| Phenol red | Absent | Optical and pH interference |
| Equilibration | 1 h at 37 °C, no CO₂ | Removes residual bicarbonate |
Two arms are worth running: one at the culture glucose concentration, one at a physiological concentration. If the phenotype is present at both, it is a property of the cell; if only at 11 mM, it is a property of the surplus.
Timing relative to activation
| Day after activation | State | Interpretation |
|---|---|---|
| 0–1 | Early activation; flux rising | Captures the induction, not the programme |
| 2–3 | Peak effector expansion | The usual window |
| 5–7 | Contraction; some death | Mixed live and dying cells; normalise carefully |
| 10+ | Memory or exhaustion depending on protocol | Different programme, different substrate |
A "T cell metabolism" result without the day is not interpretable, because glycolytic flux changes several fold across the trajectory.
Important distinction. The comparison that matters is within the same day. Effector day 3 versus memory day 14 confounds the differentiation state with time in culture, cell density and medium exhaustion.
The derived parameters, and their assumptions
| Parameter | Calculation | Assumption |
|---|---|---|
| Basal respiration | Pre-injection OCR − non-mitochondrial | Non-mitochondrial rate is stable |
| ATP-linked | Basal − oligomycin OCR | Oligomycin fully blocks ATP synthase |
| Maximal | FCCP peak − non-mitochondrial | FCCP concentration was titrated |
| Spare capacity | Maximal − basal | The cell can use it |
| Proton leak | Oligomycin OCR − non-mitochondrial | Not an artefact of oligomycin toxicity |
| Glycolysis | ECAR after glucose | Acidification is glycolytic |
| Glycolytic capacity | ECAR after oligomycin | Respiratory CO₂ contribution is negligible |
Caveat on FCCP. Uncorrected FCCP concentration produces a value that is neither maximal nor interpretable. A titration curve on the same cell type and day is required; the optimum differs between T cell states.
When SCENITH is the better choice
SCENITH measures substrate dependence per cell by flow cytometry, using translation rate as the readout under selective inhibitors.
| Situation | Seahorse | SCENITH |
|---|---|---|
| Heterogeneous population | Population average | Per-cell distribution |
| Very few cells | Signal-limited | Feasible |
| Need for sorting or phenotyping | Not compatible | Compatible |
| Absolute flux | Reports rates | Reports relative dependence |
For a population with a bimodal response — which activated T cells frequently are — the per-cell method answers the question the population average hides.
Failures that recur
- • ECAR reported as glycolytic rate without checking the respiratory contribution.
- • Protein normalisation. Activation changes protein per cell.
- • No terminal cell count, so well-to-well variation is unattributed.
- • Assay buffer glucose unstated. The baseline is set by it.
- • Day after activation unstated.
- • FCCP not titrated for that cell state.
- • Dying cells included at day 6–7, lowering the apparent flux of the population.
Where this connects
- • Immunometabolism article supplies the trajectory and the claim-level distinctions this protocol serves.
- • Glucose pillar supplies the ECAR interpretation rules.
- • Mitochondrial pillar supplies the Mito Stress Test assumptions, which apply here with the additional problem of non-adherence.
Scientific interpretation and experimental design
- • Report the buffer. Flux is measured in an artificial medium.
- • Normalise per cell, terminally counted.
- • State the day after activation.
- • Titrate FCCP for the cell state.
- • Run two glucose concentrations when the phenotype could be substrate-driven.
- • Use SCENITH for heterogeneity.
- • Exclude dying cells, or report them separately.
Selected references for further reading
- • Argüello RJ, et al. SCENITH: a flow cytometry-based method to functionally profile energy metabolism with single-cell resolution. Cell Metabolism. 2020;32:1063–1075.
- • Mookerjee SA, Gerencser AA, Nicholls DG, Brand MD. Quantifying intracellular rates of glycolytic and oxidative ATP production. Journal of Biological Chemistry. 2017;292:7189–7207.
- • Divakaruni AS, Jastroch M. A practical guide for the analysis, standardization and interpretation of oxygen consumption measurements. Nature Metabolism. 2022;4:978–994.
- • Buck MD, et al. Metabolic instruction of immunity. Cell. 2017;169:570–586.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »